Premium
Moclobemide and clomipramine in endogenous depression
Author(s) -
Koczkas C.,
Holm P.,
Karlsson A.,
Nagy A.,
Ose E.,
Pétursson H.,
Ulverås L.,
Wenedikter O.
Publication year - 1989
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1989.tb10298.x
Subject(s) - moclobemide , clomipramine , anticholinergic , depression (economics) , endogenous depression , psychology , medicine , endogeny , psychiatry , anesthesia , antidepressant , macroeconomics , economics , anxiety
– The purpose of this study was to compare moclobemide and clomipramine in endogenous depression according to the Newcastle II classification. Sixty‐two patients were allocated to either 300 mg moclobemide or 150 mg clomipramine, both given in 3 daily doses. Improvements occurred over time but differences between treatments were never statistically significant. Dizziness, tremor and anticholinergic symptoms were significantly more frequent with clomipramine.